[对于法布里病的药物护送疗法]
1Department of pediatrics, The Jikei University School of Medicine.
Brain and nerve = Shinkei kenkyu no shinpo
|October 7, 2024
概括
药理伴奏疗法 (PCT) 稳定突变酶,提供口服治疗的好处. 它的有效性依赖于特定的基因突变,但预计未来用于溶酶体疾病的应用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 药理伴奏疗法 (PCT) 通过稳定突变酶蛋白来治疗遗传疾病,提供了一种新的方法.
- 在中枢神经系统疾病中,PCT的口服和疗效比其他治疗方法具有显著的优势.
- PCT的有效性取决于患者遗传内存在特定的,可接受的基因突变.
研究的目的:
- 审查药理伴随疗法 (PCT) 的机制和应用.
- 突出PCT的优势,包括口服和中枢神经系统障碍的有效性.
- 讨论基于基因突变依赖性的PCT的局限性,并探索未来的治疗潜力.
主要方法:
- 对现有关于药理伴侣治疗的研究进行文献综述.
- 对具有特定基因突变的患者PCT疗法疗效的临床数据的分析.
- 探讨由伴侣分子稳定酶的生物化学基础.
主要成果:
- PCT在结构上稳定了突变酶蛋白,从而增加了它们的酶活性.
- PCT已证明在预防法布里心肌病和病的进展方面具有有效性.
- PCT的成功直接与患者的特定基因突变有关,限制了其普遍适用性.
结论:
- 药理伴随疗法是针对特定遗传疾病的有前途的治疗策略,特别是那些影响中枢神经系统的疾病.
- 未来PCT的开发预计将用于更广泛的溶酶体疾病.
- 考虑个体基因突变的个性化医学方法对于优化PCT结果至关重要.
相关概念视频
Molecular Chaperones and Protein Folding
17.8K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
17.8K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
144
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
144
Cystic Fibrosis: Management
144
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
144


